Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.30 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5996019 | 1.00 | TSHR (0.35) | TSHRRAB9ATFPI2AKR1C1 | |
| SCHEMBL5995016 | 0.74 | TSHR (0.33) | TSHRRAB9ATFPI2AKR1C1 | |
| SCHEMBL5995932 | 0.72 | CA2 (0.33) | — | |
| SCHEMBL5995930 | 0.72 | CA2 (0.33) | — | |
| SCHEMBL14289077 | 0.69 | TSHR (0.33) | TSHRRAB9ATFPI2AKR1C1 | |
| SCHEMBL5098846 | 0.69 | TSHR (0.33) | TSHRRAB9ATFPI2AKR1C1 | |
| SCHEMBL13632369 | 0.67 | MAPT (0.55) | TSHRRAB9ATFPI2AKR1C1 | |
| SCHEMBL14289031 | 0.67 | POLB (0.35) | TSHRRAB9ATFPI2AKR1C1 | |
| SCHEMBL19446985 | 0.67 | HSD17B10 (0.34) | TSHRRAB9ATFPI2AKR1C1 | |
| SCHEMBL8205110 | 0.67 | HSD17B10 (0.32) | TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2006-10-05 | — | — | US | disclosed |
| US-20040132709-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2004-07-08 | — | — | US | disclosed |
| US-6693095-B2 | 7-(((5-AMINO-1,2,4-THIADIAZOL-3-YL)-(Z)-(FLUORMETHOXYIMINO) -ACETYL)AMINO)-3(E)-((IMINO-1-PIPERAZINYLMETHYL)-METHYLHYDRAZONO)METHYL-3 -CEPHEM-4-CARBOXYLIC ACID TRIHYDROCHLORIDE FOR EXAMPLE | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2004-02-17 | — | — | US | disclosed |
| EP-0973780-B1 | ANTIBACTERIAL SUBSTITUTED 7-ACYLAMINO -3-(METHYLHYDRAZONO) METHYL-CEPHALOSPORINS AND INTERMEDIATES | BIOCHEMIE GMBH (AT) | 2003-07-02 | — | — | EP | disclosed |
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2003-06-19 | — | — | US | disclosed |
| EP-1300408-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono)methyl-cephalosporins and intermediates | BIOCHEMIE Gesellschaft m.b.H. (AT) | 2003-04-09 | — | — | EP | disclosed |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2002-08-22 | — | — | US | disclosed |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2002-07-11 | — | — | US | disclosed |
| EP-0973780-A1 | ANTIBACTERIAL SUBSTITUTED 7-ACYLAMINO -3-(METHYLHYDRAZONO) METHYL-CEPHALOSPORINS AND INTERMEDIATES | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998043981-A1 | ANTIBACTERIAL SUBSTITUTED 7-ACYLAMINO-3-(METHYLHYDRAZONO)METHYL -CEPHALOSPORINS AND INTERMEDIATES | BIOCHEMIE GESELLSCHAFT MBH (AT) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | TSHR 3472/4885RAB9A 383/4885TFPI2 4374/4885 |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | TSHR 3472/4885RAB9A 383/4885TFPI2 4374/4885 |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | TSHR 3472/4885RAB9A 383/4885TFPI2 4374/4885 |
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, PRMT7 | TSHR 1996/4885RAB9A 527/4885TFPI2 4227/4885 |
| US-20040132709-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | TSHR 3472/4885RAB9A 383/4885TFPI2 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.